SkinMedica, Inc.’s Desonate™ (desonide gel) 0.05% has recently been approved by the USFDA for the treatment of mild to moderate atopic dermatitis (a.k.a. eczema).
Free from alcohol, surfactants and fragrance, Desonate is a low potency topical steroid formulated in a proprietary water- based Hydrogel vehicle developed and patented by Dow Pharmaceutical Sciences, Inc.
Developed in a collaborative effort between SkinMedica (700662) and Dow Pharmaceutical Sciences, Inc. (5037183) Desonate® will be available to physicians in the first quarter of 2007.
Find more details from the SkinMedica’s press release.
Comment Preview